(Q37679951)

21 August 2017

1 reference

title

Levodopa delivery systems: advancements in delivery of the gold standard (English)

1 reference

21 August 2017

1 reference

Ndidi Ngwuluka

1

0 references

Viness Pillay

Viness Pillay

2

0 references

Yahya E Choonara

Yahya Choonara

5

0 references

Lisa C du Toit

3

Lisa C Du Toit

1 reference

21 August 2017

6

Girish Modi

1 reference

21 August 2017

Valence M. K. Ndesendo

4

Valence Ndesendo

1 reference

21 August 2017

7

Dinesh Naidoo

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Drug Delivery

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

203-224

1 reference

An essay on the shaking palsy. 1817.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A new look at James Parkinson's Essay on the Shaking Palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Present and future drug treatment for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Parkinson's disease: clinical features and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The neurobiology of dopamine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Long term motor complications of levodopa: clinical features, mechanisms, and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Dopamine neuron systems in the brain: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Intravenous levodopa administration in humans based on a two-compartment kinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

CNS gene therapy and a nexus of complexity: systems and biology at a crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Blood-brain barrier tight junction permeability and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The first miracle in neurodegenerative disease: the discovery of oral levodopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The history of dopamine and levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and alpha-methyldopa by HPLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Levodopa strengths and weaknesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Optimizing bioavailability in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

New developments in levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Prevention and treatment of motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A promising new technology for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The scientific basis for the current treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The role of COMT inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Levodopa/carbidopa/entacapone (Stalevo).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Clinical strategies to prevent and delay motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Pharmacotherapy for advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Relevance of motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Levodopa availability improves with progression of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Recognition and treatment of response fluctuations in Parkinson's disease: review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Effect of sleep deprivation on motor performance in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Low-dose clozapine improves dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Rapid intravenous loading of levodopa for human research: clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Continuous dopaminergic stimulation--from theory to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Development of microspheres for neurological disorders: from basics to clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Biodegradable microspheres for vitreoretinal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Bioadhesive microspheres as a controlled drug delivery system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Mobility of model proteins in hydrogels composed of oppositely charged dextran microspheres studied by protein release and fluorescence recovery after photobleaching

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Dual-drug delivery system based on hydrogel/micelle composites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Drug delivery to the upper small intestine window using gastroretentive technologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Gastroretentive delivery systems: a mini review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A critical review of gastric retentive controlled drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Formulation strategies for absorption windows

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Potential applications of nanotechnologies to Parkinson's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

21 January 2018

Orthostatic hypotension

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Brain drug delivery of small molecules using immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Biodegradable polymeric nanoparticles as drug delivery devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Glutathione, iron and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Levodopa-induced dyskinesia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

The hydrodynamically balanced system: a novel principle of controlled drug release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

Vector-mediated drug delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

PAMAM Dendrimers as Potential Agents against Fibrillation ofα-Synuclein, a Parkinson's Disease-Related Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903483166

10.1517/17425240903483166

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference